SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001415889-24-029682
Filing Date
2024-12-17
Accepted
2024-12-17 19:26:26
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 11164
2 EXHIBIT 99.1 JOINT FILING AGREEMENT ex-99-12182024_121227.htm EX-99.1 4715
  Complete submission text file 0001415889-24-029682.txt   17722
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Subject) CIK: 0001870404 (see all company filings)

IRS No.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92943 | Film No.: 241557288
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 398 PRIMROSE ROAD, SUITE 328 BURLINGAME CA 94010
Business Address 398 PRIMROSE ROAD, SUITE 328 BURLINGAME CA 94010 650-204-1258
YK Bioventures Opportunities GP I, LLC (Filed by) CIK: 0002042634 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A